Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma
Standard
Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma. / Schmiester, Maren; Maier, René; Riedel, René; Durek, Pawel; Frentsch, Marco; Kolling, Stefan; Mashreghi, Mir-Farzin; Jenq, Robert; Zhang, Liangliang; Peterson, Christine B; Bullinger, Lars; Chang, Hyun-Dong; Na, Il-Kang.
In: GUT MICROBES, Vol. 14, No. 1, 2081475, 01.06.2022.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma
AU - Schmiester, Maren
AU - Maier, René
AU - Riedel, René
AU - Durek, Pawel
AU - Frentsch, Marco
AU - Kolling, Stefan
AU - Mashreghi, Mir-Farzin
AU - Jenq, Robert
AU - Zhang, Liangliang
AU - Peterson, Christine B
AU - Bullinger, Lars
AU - Chang, Hyun-Dong
AU - Na, Il-Kang
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Modulation of commensal gut microbiota is increasingly recognized as a promising strategy to reduce mortality in patients with malignant diseases, but monitoring for dysbiosis is generally not routine clinical practice due to equipment, expertise and funding required for sequencing analysis. A low-threshold alternative is microbial diversity profiling by single-cell flow cytometry (FCM), which we compared to 16S rRNA sequencing in human fecal samples and employed to characterize longitudinal changes in the microbiome composition of patients with aggressive B-cell non-Hodgkin lymphoma undergoing chemoimmunotherapy. Diversity measures obtained from both methods were correlated and captured identical trends in microbial community structures, finding no difference in patients' pretreatment alpha or beta diversity compared to healthy controls and a significant and progressive loss of alpha diversity during chemoimmunotherapy. Our results highlight the potential of FCM-based microbiome profiling as a reliable and accessible diagnostic tool that can provide novel insights into cancer therapy-associated dysbiosis dynamics.
AB - Modulation of commensal gut microbiota is increasingly recognized as a promising strategy to reduce mortality in patients with malignant diseases, but monitoring for dysbiosis is generally not routine clinical practice due to equipment, expertise and funding required for sequencing analysis. A low-threshold alternative is microbial diversity profiling by single-cell flow cytometry (FCM), which we compared to 16S rRNA sequencing in human fecal samples and employed to characterize longitudinal changes in the microbiome composition of patients with aggressive B-cell non-Hodgkin lymphoma undergoing chemoimmunotherapy. Diversity measures obtained from both methods were correlated and captured identical trends in microbial community structures, finding no difference in patients' pretreatment alpha or beta diversity compared to healthy controls and a significant and progressive loss of alpha diversity during chemoimmunotherapy. Our results highlight the potential of FCM-based microbiome profiling as a reliable and accessible diagnostic tool that can provide novel insights into cancer therapy-associated dysbiosis dynamics.
KW - Adult
KW - Dysbiosis/diagnosis
KW - Flow Cytometry
KW - Gastrointestinal Microbiome/genetics
KW - Humans
KW - Lymphoma, Non-Hodgkin
KW - RNA, Ribosomal, 16S/genetics
U2 - 10.1080/19490976.2022.2081475
DO - 10.1080/19490976.2022.2081475
M3 - SCORING: Journal article
C2 - 35634713
VL - 14
JO - GUT MICROBES
JF - GUT MICROBES
SN - 1949-0976
IS - 1
M1 - 2081475
ER -
